Indoco Remedies Q2 Results: Key Dates for 2026

Board meeting is scheduled for October 27

Indoco Remedies is scheduled to report its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company has said its Board of Directors will meet on Tuesday, October 27, 2026, to consider and approve the Q2 FY2026-27 numbers. The announcement places the pharmaceutical company among firms reporting quarterly earnings during the October 27 results calendar. Investors will assess the figures against the company’s first-quarter performance and the available estimates for the following financial years. The disclosure will cover the second quarter of FY2026-27, also referred to in some earnings calendars as Q2 2027. No actual Q2 financial figures were included in the available announcement before the board meeting.

Results will cover standalone and consolidated performance

The scheduled board meeting concerns both standalone and consolidated results. Standalone numbers reflect Indoco Remedies’ own operations, while consolidated accounts include eligible group entities. This distinction matters because the company’s disclosures and market data can present financial metrics on different reporting bases. The company will also consider results for the half-year ended September 30, 2026, alongside the quarterly statement. Investors typically use the half-year disclosure to compare the first six months with the corresponding prior-year period. The company has not provided a financial outlook in the board-meeting notice.

Management call set for 3:00 PM IST

Indoco Remedies has scheduled an earnings conference call on October 27, 2026, at 3:00 PM IST. Management is expected to discuss the unaudited Q2 FY2026-27 performance and the half-year financial results with investors and analysts. The call follows the planned consideration of the results by the board. Such calls generally provide management’s comments on quarterly operations, but the company’s notice only confirms the discussion of the financial performance and outlook. The scheduled call gives shareholders an opportunity to hear management’s explanation after the results are released. Any operational updates will depend on the company’s formal presentation and comments on the day.

Q1 showed a return to reported profitability

The supplied first-quarter data showed revenue of ₹468 crore, up 6.8% from the comparable prior-year quarter. Net income was reported at ₹65 crore, compared with a net loss of ₹36 crore in Q1 2026. Earnings per share were ₹7.09, against a loss per share of ₹3.94 a year earlier. The reported profit margin was 14%, following a net loss in the prior-year first quarter. These figures provide a reference point for the October 27 release, although the available data also includes reporting metrics drawn from different financial-data formats. The Q2 announcement will be the formal source for the company’s current quarterly standalone and consolidated performance.

Revenue data shows quarterly movement

A quarterly financial table in the available data shows revenue of ₹566 crore for June 2026, compared with ₹460 crore in March 2026 and ₹435 crore in December 2025. The same table lists ₹473 crore for June 2025. Separately, a results summary lists revenue of ₹467 crore for the latest reported quarter, with year-on-year growth of 6.76%. Another standalone Q1 FY27 summary states revenue of ₹413.44 crore, down 10.0% sequentially and up 3.9% year-on-year. These differences underline the importance of checking the reporting basis, period label and source when comparing financial metrics. The company’s approved Q2 filing will clarify the reported figures for the September quarter.

Key reported and scheduled data

Trading window remains closed through October 29

Indoco Remedies said the trading window for designated persons and their immediate relatives will remain closed until October 29, 2026. This date is 48 hours after the financial results are declared. Trading-window restrictions are intended to limit dealing in securities while unpublished price-sensitive information is being considered or released. The restriction is linked to the company’s scheduled earnings disclosure. It does not represent a change in the company’s operations or financial position. The reopening date will depend on the results being declared as scheduled.

Estimates point to revenue growth over two years

Available estimates show revenue of ₹2,045.5 crore for 2027 and ₹2,315.8 crore for 2028. The same data set lists adjusted net profit of ₹9.9 crore for 2027 and ₹94.8 crore for 2028, while estimated EPS is ₹4.65 and ₹11.83, respectively. These are estimates rather than company-reported results and should not be treated as guidance from Indoco Remedies. Another available forecast expects revenue to grow by an average of 12% annually over the next two years, equal to the cited forecast for India’s pharmaceutical industry. The October 27 release will provide fresh reported information against which these estimates can be assessed.

What investors will watch in the Q2 release

The principal focus will be the company’s reported revenue, profitability and margin performance for the September quarter. Market participants will also compare the figures with the Q1 data, which indicated a return to profit from a loss in the prior-year quarter. Since the board will approve both standalone and consolidated accounts, investors will need to identify the basis used in each comparison. Commentary from management during the 3:00 PM IST call may provide context on the quarter and the half-year. Until the formal filing is released, no conclusions can be drawn on Q2 financial performance. The next confirmed event is the board meeting and earnings call scheduled for October 27, 2026.